|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Tenecteplase Reperfusion therapy in Acute ischaemic Cerebrovascular Events-Ⅱ (TRACE Ⅱ): rationale and design显示文摘Background and purpose Tenecteplase(TNK)is a promising agent for treatment of acute ischaemic stroke(AIS).We hypothesised that recombinant human TNK tissue-type plasminogen activator(rhTNK-tPA)is non-inferior to rt-PA in achieving excellent functional outcome at 90 days,when administered within 4.5 hours of ischaemic stroke onset.Methods and design Tenecteplase Reperfusion therapy in Acute ischemic Cerebrovascular Events(TRACE)is a phase Ⅲ,multicentre,prospective,randomised,open-label,blinded-end point non-inferiority study.Patients eligible for intravenous thrombolysis therapy are randomised to rhTNK-tPA 0.25 mg/kg(single bolus)to a maximum of 25 mg or rt-PA 0.9 mg/kg(10%bolus+90%infusion/1 hour)to a maximum of 90 mg.Medications considered necessary for the patient’s health may be given at the discretion of the investigator during 90-day follow-up.Study outcomes The primary study outcome is excellent functional outcome defined as modified Rankin Scale(mRS)0–1 at 90 days.Secondary efficacy outcomes include favourable functional outcome defined as mRS≤2 at 90 days,ordinal distribution of mRS and major neurological improvement on the National Institutes of Health Stroke Scale.Safety outcomes are symptomatic intracranial haemorrhage within 36 hours and death from any cause.Discussion There is no completed registration study of TNK in AIS worldwide.TRACE Ⅱ strives to provide evidence for a new drug application for rhTNK-tPA in AIS within 4.5 hours through a well-designed and rigorously executed randomised trial in China. | Shuya Li Bruce C V Campbell Lee H Schwamm Marc Fisher Mark Parsons Hao Li Yuesong Pan Yongjun Wang | 2022 | Stroke & Vascular Neurology2022，7，1： | 2 |
| 2 | A second conserved GAF domain cysteine is required for the blue/green photoreversibility of cy- anobacteriochrome TIr0924 from Thermosynecho- coccus elongates 显示文摘 | Rockwell N C Njuguna S L Roberts L Castillo E Parson V L Dwojak S Lagarias J C Spiller S C | 2008 | Biochemistry2008，47，： | 1 |
| 3 | Two monoclonal an tibodies(cc17,cc29)recognizing an antigen(Bo5)on bovine T lymphocytes,analogous to human CD5显示文摘 | Howard C J,Parsons K P,Jones B V | 1988 | Vet Immunol1988，13，： | 1 |
| 4 | Information flow and influence in collective choice显示文摘 | Stasser O Abele S and Parsons S V | 2012 | Group Processes & Intergroup Rela- tions2012，15，5： | 1 |
| 5 | Transformation of poplar by agrobacterium tumefaciens显示文摘 | Parson T J Sinkar V P Stettler R F | 1986 | Biotechnology1986，4，6： | 1 |
| 6 | Sex differences in mortality after acute myocardial infarction:changes from 1994 to2006显示文摘 | Vaccarino V Parsons L Peterson ED | 2009 | Arch Intern Med2009，169，： | 1 |
| 7 | The use of intra-aortic balloon counter pulsation in patients with cardiogenic shock complicating acute myocardial infarction 显示文摘 | BARRON H V EVERY N R PARSONS L S | 2001 | Am Heart J2001，141，6： | 1 |
| 8 | Getting to the bottom line : an exploration of gender and earnings quality 显示文摘 | Krishnan G V Parsons L M | 2008 | Journal of Bus- iness Ethics2008，78，1： | 1 |
| 9 | Nutritional characteristics of corn distillers dried grains with solubles as affected by the amounts of grains versus solubles and different processing techniques 显示文摘 | Martinez-Amezcua C Parsons C M Singh V | | Pouh Sci0，86，： | 1 |
| 10 | Tranexamic acid for intracerebral haemorrhage within 2 hours of onset: protocol of a phase Ⅱ randomised placebo-controlled double-blind multicentre trial显示文摘Rationale Haematoma growth is common early after intracerebral haemorrhage(ICH),and is a key determinant of outcome.Tranexamic acid,a widely available antifibrinolytic agent with an excellent safety profile,may reduce haematoma growth.Methods and design Stopping intracerebral haemorrhage with tranexamic acid for hyperacute onset presentation including mobile stroke units(STOP-MSU)is a phase Ⅱ double-blind,randomised,placebo-controlled,multicentre,international investigator-led clinical trial,conducted within the estimand statistical framework.Hypothesis In patients with spontaneous ICH,treatment with tranexamic acid within 2 hours of onset will reduce haematoma expansion compared with placebo.Sample size estimates A sample size of 180 patients(90 in each arm)would be required to detect an absolute difference in the primary outcome of 20%(placebo 39%vs treatment 19%)under a two-tailed significance level of 0.05.An adaptive sample size re-estimation based on the outcomes of 144 patients will allow a possible increase to a prespecified maximum of 326 patients.Intervention Participants will receive 1 g intravenous tranexamic acid over 10 min,followed by 1 g intravenous tranexamic acid over 8 hours;or matching placebo.Primary efficacy measure The primary efficacy measure is the proportion of patients with haematoma growth by 24±6 hours,defined as either≥33%relative increase or≥6 mL absolute increase in haematoma volume between baseline and follow-up CT scan.Discussion We describe the rationale and protocol of STOP-MSU,a phase Ⅱ trial of tranexamic acid in patients with ICH within 2 hours from onset,based in participating mobile stroke units and emergency departments. | Nawaf Yassi Henry Zhao Leonid Churilov Bruce C V Campbell Teddy Wu Henry Ma Andrew Cheung Timothy Kleinig Helen Brown Philip Choi Jiann-Shing Jeng Annemarei Ranta Hao-Kuang Wang Geoffrey C Cloud Rohan Grimley Darshan Shah Neil Spratt Der-Yang Cho Karim Mahawish Lauren Sanders John Worthington Ben Clissold Atte Meretoja Vignan Yogendrakumar Mai Duy Ton Duc Phuc Dang Nguyen Thai My Phuong Huy-Thang Nguyen Chung Y Hsu Gagan Sharma Peter J Mitchell Bernard Yan Mark W Parsons Christopher Levi Geoffrey A Donnan Stephen M Davis | 2022 | Stroke & Vascular Neurology2022，7，2： | 1 |
| 11 | Transformation of poplar by Agrobacterium tumefaciens 显示文摘 | PARSON T J SINKAR V P STETTLER R F | 1986 | Biotechnology1986，4，6： | 1 |
| 12 | Echolocation calls and wing morphology of bats from the West Indies 显示文摘 | Gennings N V Parsons S Barlow K E | 2004 | Acta Chiropterologica2004，6，1： | 1 |
| 13 | Perfusion computed tomography:prediction of final infarct extent and stroke outcome显示文摘 | Parsons MW Pepper EM Chan V | 2005 | Ann Neurol2005，58，5： | 1 |
| 14 | Use of microsatelliteloci to classify individuals by relatedness 显示文摘 | Bluin M Parsons M Lacaille V et al | 1996 | Molecular E-cology1996，5，： | 1 |
| 15 | The use of intra-aortic balloon counterpulation in patients with cardiogenic shock complicating acute myocardial infarction 2显示文摘 | BARRON H V EVERY N R PARSONS L S | 2001 | Am Heart J2001，141，： | 1 |
| 16 | Contrasting patterns of litterfall seasonality and seasonal changes in lit- ter decomposability in a tropical rainforest region 显示文摘 | Parsons S A Valdez-Ramirez V Congdon R A | 2014 | Biogeosciences Discuss2014，11，： | 1 |
| 17 | In vivo evidence for functional NMDA receptor blockade by memantine in rat hippocampal neurons 显示文摘 | Szegedi V Juhasz G Parsons CG | 2010 | J Neural Transm2010，117，10： | 1 |
| 18 | Colorado SheepID pro- ject:Using RFID or tracking sheep显示文摘 | Parsons J Kimberling C Parson G V | 2005 | Journal of Ani-mal Science2005，，83： | 1 |
| 19 | A third distinct tumor necrosis factor receptor of orthopoxviruses 显示文摘 | Loparev V N Parsons J M Knight J C | 1998 | Proceedings of the National Academy of Sciences of the United States ofAmerica1998，95，7： | 1 |
| 20 | Quality of care by classification of myocardial infarction: treatment patterns for ST-segment elevation vs non-ST-segment elevation myocardial infarction 显示文摘 | Roe M T Parsons L S Pollack C V Jr | 2005 | Arch Intern Med2005，165，14： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员